Cardiovascular aspects of antipsychotics

Current Opinion in Psychiatry

Volumn 23, Issue 6, 2010, Pages 574-581

  Raedler, Thomas J ^a,b  

^a Department of Psychiatry ^*  (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Antipsychotics; cardiovascular disease; metabolic syndrome; mortality; schizophrenia

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; DROPERIDOL; GLUCOSE; HALOPERIDOL; LIPOPROTEIN; MESORIDAZINE; OLANZAPINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE;

ABDOMINAL OBESITY; BLOOD PRESSURE; BODY WEIGHT; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HEART ARRHYTHMIA; HEART DEATH; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LIFE EXPECTANCY; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; MORTALITY; MYOCARDITIS; ORTHOSTATIC HYPERTENSION; QT PROLONGATION; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; TACHYCARDIA; TREATMENT RESPONSE; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BODY WEIGHT; CARDIOMYOPATHIES; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MYOCARDITIS; RISK FACTORS; SCHIZOPHRENIA;

EID: 77958165098     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/YCO.0b013e32833f46c9     Document Type: Review

References (117)

1. Kuehn BM. Questionable antipsychotic prescribing remains common, despite serious risks. JAMA 2010; 303:1582-1584.
2. Leslie DL, Mohamed S, Rosenheck RA. Off-label use of antipsychotic medications in the department of Veterans Affairs healthcare system. Psychiatr Serv 2009; 60:1175-1181.
3. Brown S. Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry 1997; 171:502-508.
4. Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150:1115-1121.
5. Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA 2007; 298:1794-1796.
6. Hennekens CH. Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia. J Clin Psychiatry 2007; 68 (Suppl 4):4-7.
7. Capasso RM, Lineberry TW, Bostwick JM, et al. Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort - 1950-2005. Schizophr Res 2008; 98:287-294.
8. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007; 68 (Suppl 4):8-13.
9. Sowden GL, Huffman JC. The impact of mental illness on cardiac outcomes: a review for the cardiologist. Int J Cardiol 2009; 132:30-37.
10. Halpert S, McFarlane SI. When the heart and the mind collide: cardiovascular risk factors and antipsychotic use in the schizophrenic population. J Cardiometab Syndr 2009; 4:1-5.
11. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006; 3:A42.
12. Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001; 58:844-850.
13. Miller BJ, Paschall CB 3rd, et al. Mortality and medical comorbidity among patients with serious mental illness. Psychiatr Serv 2006; 57:1482-1487.
14. Osborn DP, Levy G, Nazareth I, et al. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Arch Gen Psychiatry 2007; 64:242-249.
15. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007; 64:1123-1131.
16. Brown S, Kim M, Mitchell C, et al. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry 2010; 196:116-121.
17. Tran E, Rouillon F, Loze J, et al. Cancer mortality in patients with schizophrenia: an 11-year prospective cohort study. Cancer 2009; 115:3555-3562.
18. Laursen TM, Nordentoft M. Heart disease treatment and mortality in schizophrenia and bipolar disorder: changes in the Danish population between 1994 and 2006. J Psychiatr Res 2010. [Epub ahead of print]
19. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374:620-627.
20. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005; 80:45-53.
21. Bresee LC, Majumdar SR, Patten SB, et al. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res 2010; 117:75-82.
22. Bobes J, Arango C, Aranda P, et al., CLAMORS Study Collaborative Group. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res 2007; 90:162-173.
23. Osborn DP, Nazareth I, King MB. Risk for coronary heart disease in people with severe mental illness: cross-sectional comparative study in primary care. Br J Psychiatry 2006; 188:271-277.
24. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009; 119:4-14.
25. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223.
26. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80:19-32.
27. Hägg S, Lindblom Y, Mjörndal T, et al. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006; 21:93-98.
28. Arango C, Bobes J, Aranda P, et al. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study. Schizophr Res 2008; 104:1-12.
29. Schorr SG, Slooff CJ, Bruggeman R, Taxis K. The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year. J Psychiatr Res 2009; 43:1106-1111.
30. Birkenaes AB, Opjordsmoen S, Brunborg C, et al. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. J Clin Psychiatry 2007; 68:917-923.
31. van Winkel R, De Hert M, Van Eyck D, et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord 2008; 10:342-348.
32. Saddichha S, Manjunatha N, Ameen S, et al. Metabolic syndrome in first episode schizophrenia: a randomized double-blind controlled, short-term prospective study. Schizophr Res 2008; 101:266-272.
33. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371:1085-1097.
34. Perez-Iglesias R, Crespo-Facorro B, Amado JA, et al. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry 2007; 68:1733-1740.
35. Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, et al. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-na?̈ve population. Schizophr Res 2008; 99:13-22.
36. Graham KA, Cho H, Brownley KA, et al. Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects. Schizophr Res 2008; 101:287-294.
37. Graham KA, Perkins DO, Edwards LJ, et al. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry 2005; 162:118-123.
38. Correll CU, Frederickson AM, Kane JM, et al. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 2006; 67:575-583.
39. Correll CU, Frederickson AM, Kane JM, et al. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007; 89:91-100.
40. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008; 13:27-35.
41. Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand 2009; 119:171-179.
42. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment: pharmacological mechanisms. Pharmacol Ther 2010; 125:169-179.
43. Kim SF, Huang AS, Snowman AM, et al. From the Cover: antipsychotic druginduced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A 2007; 104:3456-3459.
44. Vik-Mo AO, Birkenaes AB, Fernø J, et al. Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients. Int J Neuropsychopharmacol 2008; 11:679-684.
45. L'Italien GJ, Casey DE, Kan HJ, et al. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. J Clin Psychiatry 2007; 68:1510-1516.
46. Meyer JM, Davis VG, Goff DC. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res 2008; 101:273-286.
47. Meyer JM, Davis VG, McEvoy JP, et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res 2008; 103:104-109.
48. Daumit GL, Goff DC, Meyer JM, et al. Antipsychotic effects on estimated 10- year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 2008; 105:175-187.
49. Blonde L, Kan HJ, Gutterman EM, et al. Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. J Clin Psychiatry 2008; 69:741-748.
50. Saarni SE, Saarni SI, Fogelholm M, et al. Body composition in psychotic disorders: a general population survey. Psychol Med 2009; 39:801-810.
51. Henderson DC, Borba CP, Daley TB. Dietary intake profile of patients with schizophrenia. Ann Clin Psychiatry 2006; 18:99-105.
52. Ryan MC, Thakore JH. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 2002; 71:239-257.
53. Allison DB, Mentore JL, Heo M, et al. Antipsychotic induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156:1686-1696.
54. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161:1334-1349.
55. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373:31-41.
56. Parsons B, Allison DB, Loebel A, et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res 2009; 110:103-110.
57. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of secondgeneration antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302:1765-1773.
58. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160:290-296.
59. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70:1-17.
60. Olfson M, Marcus SC, Corey-Lisle P, et al. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry 2006; 163:1821-1825.
61. Koro CE, Fedder DO, L'Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002; 59:1021-1026.
62. Lund BC, Perry PJ, Brooks JM, et al. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claimsbased approach. Arch Gen Psychiatry 2001; 58:1172-1176.
63. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32 (Suppl 1):S1-S201.
64. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in firstepisode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160:284-289.
65. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002; 59:337-345.
66. SernyakMJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159:561-566.
67. Smith M, Hopkins D, Peveler RC, et al. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2008; 192:406-411.
68. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 (Suppl 1): 1-93.
69. Yood MU, DeLorenze G,QuesenberryCP Jr, et al. The incidence of diabetes in atypical antipsychotic users differs according to agent: results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf 2009; 18:791-799.
70. Baker RA, Pikalov A, Tran QV, et al. Atypical Antipsychotic Drugs and Diabetes Mellitus in the US Food and Drug Administration Adverse Event Database: a systematic Bayesian signal detection analysis. Psychopharmacol Bull 2009; 42:11-31.
71. Hasnain M, Vieweg WV, Fredrickson SK. Metformin for atypical antipsychotic- induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions. CNS Drugs 2010; 24:193-206.
72. Michelsen JW, Meyer JM. Cardiovascular effects of antipsychotics. Expert Rev Neurother 2007; 7:829-839.
73. Mackin P. Cardiac side effects of psychiatric drugs. Hum Psychopharmacol 2008; 23 (Suppl 1):3-14.
74. Ray WA, Meredith S, Thapa PB, et al. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001; 58:1161-1167.
75. Hennessy S, Bilker WB, Knauss JS. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ 2002; 325:1070.
76. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360:225-235.
77. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004; 24:62-69.
78. Strom BL, Faich GA, Reynolds RF. The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics. J Clin Psychiatry 2008; 69:114-121.
79. Kasper S, Möller HJ, Hale A. The European postmarketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment. Eur Arch Psychiatry Clin Neurosci 2010; 260:59-68.
80. Thomas SH, Drici MD, Hall GC, et al. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatr Scand (in press).
81. Mackin P, Young AH. QTc interval measurement and metabolic parameters in psychiatric patients taking typical or atypical antipsychotic drugs: a preliminary study. J Clin Psychiatry 2005; 66:1386-1391.
82. Novotny T, Florianova A, Ceskova E, et al.Monitoring of QT interval in patients treated with psychotropic drugs. Int J Cardiol 2007; 117:329-332.
83. Ramos-Ríos R, Arrojo-Romero M, Paz-Silva E, et al. QTc interval in a sample of long-term schizophrenia inpatients. Schizophr Res 2010; 116:35-43.
84. Volpi S, Heaton C, Mack K, Hamilton JB, et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry 2009; 14:1024-1031.
85. Buckley NA, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Saf 2000; 23:215-228.
86. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebocontrolled trials. JAMA 2005; 294:1934-1943.
87. Sacchetti E, Turrina C, Valsecchi P. Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review. Drug Saf 2010; 33:273-288.
88. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ 2008; 337:a1227.
89. Liperoti R, Pedone C, Lapane KL, et al. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med 2005; 165:2677-2682.
90. Hägg S, Bate A, Stahl M, et al. Associations between venous thromboembolism and antipsychotics. A study of the WHO database of adverse drug reactions. Drug Saf 2008; 31:685-694.
91. Hägg S, Spigset O, Söderström TG. Association of venous thromboembolism and clozapine. Lancet 2000; 355:1155-1156.
92. Annamraju S, Sheitman B, Saik S, et al. Early recognition of clozapineinduced myocarditis. J Clin Psychopharmacol 2007; 27:479-483.
93. Merrill DB, Ahmari SE, Bradford JM, et al. Myocarditis during clozapine treatment. Am J Psychiatry 2006; 163:204-208.
94. Kilian JG, Kerr K, Lawrence C, et al. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999; 354:1841-1845.
95. Coulter DM, Bate A, Meyboom RH, et al. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ 2001; 322:1207-1209.
96. Reinders J, Parsonage W, Lange D, et al. Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Aust N Z J Psychiatry 2004; 38:915-922.
97. Haas SJ, Hill R, Krum H, Liew D, et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 2007; 30:47-57.
98. Hill GR, Harrison-Woolrych M. Clozapine and myocarditis: a case series from the New Zealand Intensive Medicines Monitoring Programme. N Z Med J 2008; 121:68-75.
99. Merrill DB, Dec GW, Goff DC. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol 2005; 25:32-41.
100. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596-601.
101. Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 2006; 51:492-501.
102. De Hert M, Dekker JM, Wood D, et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009; 24:412-424.
103. Haupt DW, Rosenblatt LC, Kim E, et al. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second- generation antipsychotic agents. Am J Psychiatry 2009; 166:345-353.
104. Alvarez-Jiménez M, Hetrick SE, Gonzá lez-Blanch C, et al. Nonpharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 2008; 193:101-107.
105. Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 2010; 35:1520-1530.
106. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006; 86: 15-22.
107. Himelhoch S, Leith J, Goldberg R, et al. Care and management of cardiovascular risk factors among individuals with schizophrenia and type 2 diabetes who smoke. Gen Hosp Psychiatry 2009; 31:30-32.
108. Laursen TM, Munk-Olsen T, Agerbo E, et al. Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch Gen Psychiatry 2009; 66:713-720.
109. Kisely S, Campbell LA, Wang Y. Treatment of ischaemic heart disease and stroke in individuals with psychosis under universal healthcare. Br J Psychiatry 2009; 195:545-550.
110. Callaghan RC, Boire MD, Lazo RG, et al. Schizophrenia and the incidence of cardiovascular morbidity: a population-based longitudinal study in Ontario, Canada. Schizophr Res 2009; 115:325-332.
111. Winterer G. Why do patients with schizophrenia smoke? Curr Opin Psychiatry 2010; 23:112-119.
112. Kelly DL, McMahon RP, Wehring HJ, et al. Cigarette Smoking and Mortality Risk in People With Schizophrenia. Schizophr Bull 2009. [Epub ahead of print]
113. Bobes J, Arango C, Garcia-Garcia M, et al. Healthy lifestyle habits and 10- year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr Res 2010; 119:101-109.
114. De Hert M, Correll CU, Cohen D. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophr Res 2010; 17:68-74.
115. Kelly DL, McMahon RP, Liu F, et al. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry 2010; 71:304-311.
116. Kelly DL, Wehring HJ, Linthicum J, et al. Cardiac-related findings at autopsy in people with severe mental illness treated with clozapine or risperidone. Schizophr Res 2009; 107:134-138.
117. Morrato EH, Druss B, Hartung DM, et al. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry 2010; 67:17-24.